Search clinical trials for: Atezolizumab(Tecentriq)

Total 753 results

Chonnam National University Hospital
Roche Pharma AG

Completed

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] (BUDDY)

Lung Neoplasm Malignant

Korea, Republic of
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
Oncology Institute of Southern Switzerland
Ente Ospedaliero Cantonale, Bellinzona; Clinical Trial Unit Ente Ospedaliero... and other collaborators

Recruiting

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

NSCLC Stage IV

Switzerland
Hoffmann-La Roche

Completed

A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
McGill University Health Centre/Research Institute...

Unknown

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

Safety Issues

Canada
National Taiwan University Hospital
Roche Pharma AG; Ipsen

Recruiting

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Metastatic Cancer | Squamous Cell Carcinoma

Taiwan
Hoffmann-La Roche

Completed

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

Belgium, France, Spain
Hoffmann-La Roche

Completed

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

Solid Tumors

United States, Denmark, Spain, Canada, France, Italy, Netherlands
Spanish Oncology Genito-Urinary Group
Roche Farma, S.A; Dynamic Science S.L.

Active, not recruiting

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Bladder Cancer

Spain
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Carcinoma, Non-Small Cell Lung | Urothelial Carcinoma | Triple Negative Breast Carcinoma

Korea, Republic of
I-Mab Biopharma US Limited

No longer available

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

Cancer

United States
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma

France
Hoffmann-La Roche

Withdrawn

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)
Darell Bigner
Genentech, Inc.; Istari Oncology, Inc.

Withdrawn

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Malignant Glioma
Oslo University Hospital

Terminated

Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC (COM-IT-1)

Non-small Cell Lung Cancer

Norway
National Cancer Center, Korea
Roche Korea co.,Ltd.

Recruiting

Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC (Atezolizumab)

Small Cell Lung Cancer Recurrent

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL)

Carcinoma, Non-Small-Cell Lung

Italy, Netherlands, Argentina, Brazil, China, Denmark, Greece, Panama, Spain, United Arab Emirates, United Kingdom, Mexico, Poland, Peru, Philippines, Costa Rica, Malaysia, Morocco, Latvia, Lebanon, Sweden, Slovenia, Colombia, Guatemala
Genentech, Inc.

Completed

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (B-F1RST)

Non-Small Cell Lung Cancer

United States
Health Pharma Professional Research

Withdrawn

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced | Malignant Pleural Mesothelioma, Unresectable

Mexico
Gulam Manji
Genentech, Inc.; Halozyme Therapeutics

Terminated

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC)

Pancreatic Ductal Adenocarcinoma

United States
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Solid Tumor

United States, Spain, Canada, United Kingdom, Denmark, France, Germany, Israel, Italy, Netherlands, Switzerland
Hoffmann-La Roche

Completed

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Solid Tumors

United States, Netherlands, Denmark, Spain, Canada, France
Jun Zhang, MD, PhD
Genentech, Inc.; Exelixis

Not yet recruiting

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1)

Lung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
BioLineRx, Ltd.
Genentech, Inc.

Terminated

A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

Acute Myeloid Leukemia

Israel, Spain, United States, Czechia, Poland, Slovakia
Turnstone Biologics, Corp.

Terminated

This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers (Kingfisher)

HPV-Associated Cancers

United States, Canada
Hoffmann-La Roche

Completed

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

Solid Cancers

United States, Belgium, France, Spain
Genentech, Inc.

Approved for marketing

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Urothelial Carcinoma

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Solid Tumors

Hungary, United States, Korea, Republic of, Belgium, Germany, United Kingdom
Alain Algazi
Genentech, Inc.

Recruiting

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Carcinoma | Cancer | Head and Neck Cancer | Squamous Cell Carcinoma

United States
Washington University School of Medicine
Eli Lilly and Company; ImmunityBio, Inc.

Withdrawn

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)

Prostatic Neoplasms, Castration-Resistant

United States, Korea, Republic of, Belgium, United Kingdom, Canada, China, Denmark, France, Greece, Poland, Spain, Italy, Czechia, Japan, Switzerland, Australia, Germany, Austria, Hungary, Russian Federation, Taiwan
Genentech, Inc.

Completed

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumor

United States, Korea, Republic of, Spain, France
Genentech, Inc.

Completed

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Non-Small Cell Lung Cancer

United States, France, United Kingdom, Belgium, Netherlands
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
Nykode Therapeutics ASA
Roche Pharma AG; GOG Foundation

Not yet recruiting

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Cervical Cancer | HPV-Related Malignancy | HPV-Related Cervical Carcinoma
Hoffmann-La Roche

Terminated

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Genprex, Inc.

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)

Small Cell Lung Cancer Extensive Stage

United States
Institut Curie
Roche Pharma AG; Replimune Inc.

Not yet recruiting

"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (neoBREASTIM)

Triple Negative Breast Neoplasms

France
Hoffmann-La Roche

Completed

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Lymphoma

United States, France, Germany, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma

Poland, United States, Germany
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
NeoImmuneTech
Immune Oncology Network

Terminated

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Melanoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Advanced Solid Tumors

Tumors

France, United States, Denmark, Ireland, Italy, Turkey, United Kingdom, Canada, Brazil, Spain, Poland, Netherlands, Germany, Russian Federation, Austria, Finland, Norway, Switzerland
Spanish Lung Cancer Group

Completed

Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis (ATEZO-BRAIN)

Non-small Cell Lung Cancer Stage IV

Spain
The Lymphoma Academic Research Organisation

Completed

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa Associated Lymphoid Tissue

France
Hoffmann-La Roche

Completed

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

Solid Tumors

United States, Denmark, Spain, Switzerland, Netherlands, Canada
Niguarda Hospital

Recruiting

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation (MOLTO)

CLL Transformation

Italy, Switzerland
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Hoffmann-La Roche

Completed

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Malignant Melanoma

United States, Australia, Brazil, Spain, South Africa, Ukraine, Bosnia and Herzegovina

Search clinical trials for: Atezolizumab(Tecentriq)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations